Page 175 - 2021_09-Haematologica-web

HBB genotype in TDT in Cyprus
Table 3. Incidence rates for mortality by cause and period of follow-up.
Heart Liver Cancer Infection Other Overall
N Incidence N Incidence N Incidence N Incidence N Incidence N Incidence Patient-years
(95% CI)
4 7.5 (2.8–20.1) 21 41.3 (26.9–63.3) 13 27.4 (15.9–47.1) 6 15.3 (6.9–34.1) 44 23.1 (17.2–31.0)
(95% CI)
1 1.9 (0.27–13.3) 0 2 3.9 0 2 4.2 (1.1–16.8) 3 5 12.8 (5.3–30.7) 4 10 5.3 (2.0–8.5) 7
(95% CI)
0.00 2
0.00 4 6.3 (2.0–19.6) 4 10.2 (3.8–27.2) 5
3.7 (1.0–6.4) 15
(95% CI)
3.77 (0.9–15.0) 4 7.9 (3.0–20.9) 6 8.4 (3.2–22.4) 4 12.8 (5.3–30.7) 4 7.9 (4.7–13.1) 18
(95% CI)
7.5 (2.8–20.1) 11.8 (5.3–26.2) 8.4 (3.2–22.4) 10.2 (3.8–27.2) 9.4 (6.0–15.0)
(95% CI) of follow-up
1980-1989 1990-1999 2000-2009 2010-2018
1980-2018
11 20.7 (11.5–37.4) 33 64.9 (46.2–91.2) 26 54.8 (37.3–80.3) 24 61.3 (41.1–91.3) 94 49.3 (40.3–60.3)
5,310.7 5,085.7 4,747.9 3,915.8 19,060.0
Incidence presented as events per 10,000 patient-years; 95% CI: 95% confidence interval.
AB
Figure 2. Kaplan- Meier curves for sur- vival during follow-up 2000 to 2018 show- ing the effects of risk factors with statisti- cally significant effects in univariate analysis. (A) Survival of the overall cohort, and categorized by (B) sex, (C) HBB genotype, (D) year of birth, (E) splenectomy during childhood, and (F) type of chelation ther- apy. DFO: deferoxam- ine; DFP: deferiprone; DFX: deferasirox.
CD
EF
haematologica | 2021; 106(9)
2463